Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Advances in immunotherapy for non-melanoma skin cancer

Paolo Ascierto • 12 Sep 2022
ESMO 2022
Merkel Cell Carcinoma Skin Cancer

Paolo Ascierto, MD, National Tumor Institute Fondazione G. Pascale, Naples, Italy, discusses recent advances in immunotherapy for merkel cell carcinoma, cutaneous squamous cell carcinoma, and basal cell carcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Paolo Ascierto

2:03
7-y results from CheckMate 238: adjuvant NIVO vs IPI in resected stage III/IV melanoma
Paolo Ascierto • 21 Oct 2023
2:03
7-year results from CheckMate 238: adjuvant nivolumab in melanoma
Paolo Ascierto • 21 Oct 2023
2:38
Updates in melanoma at ESMO 2022
Paolo Ascierto • 12 Sep 2022
2:14
Standard-of-care and future research directions for advanced squamous cell carcinoma
Paolo Ascierto • 12 Sep 2022

Related Videos

1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
2:12
Novel immunotherapeutic approaches to treat patients with melanoma
Christoffer Gebhardt • 9 Apr 2024
1:22
INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
Christoffer Gebhardt • 9 Apr 2024
2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals